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Summary The p53 protein has been proposed as a modulator of the Wilms' tumour-suppressor protein (WT1) transcriptional regulation
activity. To investigate this putative p53 role, the promoter P3 of the mouse insulin-like growth factor 11 gene (Igf2) was used as a target for
WT1 regulation in primary cell cultures derived from p53 wild-type (p53F+1) and knock-out (p53-1-) mouse embryos. In these cells, the WT1
transcriptional activity was observed to be independent of p53 genotype. Furthermore, the two WT1 zincfinger (ZF) isoforms were forthe first
time found to have opposite effects on gene expression from a single promoter in the same cell type, WT1[-KTS] activating Igf2 P3, whereas
WT1[+KTS] repressed its activity. In addition, we have mapped the WT1 binding sites and investigated the effect on WT1 binding activity of
individual ZF deletions and Denys-Drash syndrome point mutations to this target.
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Wilms' tumour is a paediatric renal neoplasm that affects 1 in
10 000 children and occurs in both sporadic and familial forms
(Matsunaga, 1981; Ward, 1997). The Wilms' tumour-associated
gene WTI was isolated by positional cloning based on constitu-
tional deletions of chromosome lIpl3 found in patients with the
WAGR syndrome (Wilms' tumour, aniridia, genitourinary malfor-
mation and mental retardation) (Call et al, 1990; Gessler et al,
1990). Mutational analysis has demonstrated inactivation of WTI
in approximately 15% of Wilms' tumours (reviewed by Hastie,
1994), and reintroduction of WTI into a Wilms' tumour cell line
resulted in growth suppression consistent with its role as a tumour-
suppressor gene (Haber et al, 1993).
WTI encodes a transcription factor containing four consecutive
Cys2-His2 zincfingers (ZF) intheC-terminus and aproline- andglut-
amine-rich amino acid sequence in the N-terminus thatincludes both
positive and negative transcriptional regulatory domains (Madden et
al, 1991; Wang et al, 1993). Alternative RNA splicing events lead to
the production of four distinct WTI isoforms (Haber et al, 1991).
Alternative splice I results in the inclusion or exclusion of 17 amino
acidsN-terminal oftheZFs, whereas alternative splice IIinserts three
amino acids [Lys-Thr-Ser (KTS)] between ZFs 3 and 4. Thus, the
four resulting isoforms include two distinct types of DNA-binding
domain, WT1[-KTS] and WT1[+KTS]. The KTS-containing tran-
scripts predominate, representing 80% ofall WT1 transcripts (Haber
et al, 1991). ZFs 2 to 4 ofWT1 show a high degree ofhomology to
the three ZFs of the early growth response gene product EGRI
(Morris et al, 1991), and WT1[-KTS] binds the EGRI consensus
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binding site (5'-GCGGGGGCG-3'). WT1[+KTS] isoforms bind
weakly to this sequence, presumably because the three amino acid
insertion alters the distance between ZFs 3 and 4. Constitutional
point mutations in the WT1 DNA-binding domain lead to
Denys-Drash syndrome (DDS), a condition characterized by renal
failure, Wilms' tumour and pseudohermaphroditism (reviewed by
Bruening andPelletier, 1994).
In transient transfection experiments, WT1 was shown to
repress the transcription ofa numberofgrowth-related genes, such
as the insulin-like growth factor II gene (IGF2) (Drummond et al,
1992). More recently it has been established that WT1 may
equally function as a transactivator (Wang et al, 1993; Reddy et al,
1995; Cook et al, 1996), indicating that it could be a bifunctional
regulator of transcription in vivo. Furthermore, transcriptional
regulation by WT1 appears to be cell type specific (Madden et al,
1993; Nichols et al, 1995; Werner et al, 1995), suggesting that
WT1 may interact with cell-type specific co-factors to mediate
either activation or repression of target genes. The p53 tumour-
suppressor protein has been proposed as one such co-factor.
Maheswaran et al (1993) have presented evidence that p53
physically associates with WT1 in transfected cells and that WTI
transcriptional activity might be modulated by p53. Whereas in
NIH-3T3 cells WT1[-KTS] repressed expression, its transfection
into Saos-2 cells, which lack endogenous p53, resulted in
increased transcription from a promoter into which EGR1
consensus binding sites had been added.
To investigate this putative role of p53 in modulating the
transcriptional regulation activity of WT1, we have used the P3
promoter of the mouse IGF2 gene (Igf2; Rotwein and Hall, 1990)
as a target for WT1 transcriptional regulation in primary cell
cultures derived from p53 wild-type (p53+'+) and knock-out
(p534-) mouse embryos. We observed that thep53 genotype does
not affect WT1 transcriptional activity, at least in these cells,
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which contrasts with the findings of Maheswaran et al (1993).
Furthermore, the two WT1 ZF isoforms were for the first time
found to have opposite effects on gene expression from a single
promoter in the same cell type, WTI[-KTS] activating Ig2
promoterP3, whereas WT1[+KTS] repressed its activity.
In addition, to analyse the effect of WT1 on Igf2 P3 transcrip-
tional activity, we have mapped the WT1 binding sites to this
target, compared them with the EGR1 binding sites, and investi-
gated the effect of individual ZF deletions and DDS point muta-
tions on WT1 binding activity. This revealed that WT1[+KTS] and
EGR1 bind to different subsets ofthe WT1[-KTS] binding sites in
Igf2 P3, that the deletion ofindividual ZFs affects WTI binding in
different ways and that the single amino acid substitutions found in
DDS patients abolish WT1 binding to this promoter.
MATERIALS AND METHODS
Plasmids and molecular cloning
The transcriptional fusion between the Igf2 P3 promoter (isolated
from cosIGF4; Rotwein and Hall, 1990) and the firefly luciferase
reporter gene, pP3MM, was previously described (Caricasole and
Ward, 1993). To construct WT1 (pCMV-KTS, pCMV+KTS,
pCMV-Drash) and EGRI (pCMV-EGR) mammalian expression
vectors, the corresponding murine cDNA sequences (Lemaire et
al, 1990; Buckler et al, 1991) were subcloned into pcDNA I/Amp
(Invitrogen), downstream of the cytomegalovirus enhancer/
promoter. A control vector, pCMV-REV, was obtainedby inserting
the WT1-KTS cDNA in the reverse orientation. The bacterial
expression constructs used to prepare glutathione S-transferase
(GST) fusion proteins were formed using the pGEX-3X vector
(Pharmacia) and cDNA sequences encoding either WT1 or EGRI
ZF domains. Details of EGRI (Caricasole et al, 1996) and both
wild-type (Bickmore et al, 1992) and mutant WT1 constructs
(Little et al, 1995) were published elsewhere.
Nucleic acid-protein interaction studies
Glutathione S-transferase (GST) fusion proteins used in DNAase I
footprinting and gel electrophoretic mobility shift (gel-shift) assays
werebacterially expressed, recoveredby sonication, affinitypurified
andquantified as previously described (Caricasole etal, 1996).
The Igf2 P3 promoter gel-shift and footprinting probes were
derived from a 236bpXhoI/XbaI fragment frompBstP3, spanning
nucleotides -162 to +70. For gelshift analysis the probe was
double digested, alkaline phosphatase-treated, gel-purified with
Geneclean II (Bio 101) and labelled. For DNAase I footprinting,
the plasmid was first cut with Xho I, dephosphorylated and cut
with Xba I, and the fragment gel-purified and end-labelled.
Typically, probes were prepared by y_32P end-labelling 100 ng of
the DNA fragment with T4 polynucleotide kinase (Promega) to
specific activities of 5-10 x 107cpm jig-1. Between 1% and 5% of
the labelled DNA was used per reaction.
Binding reactions were carried out for 30 min on ice, in 20-jl
(gel-shifts) or 50-pl(footprinting) volumes ofbinding buffer(50 mm
Hepes, pH 7.5, 50 mm potassium chloride, S mm magnesium chlo-
ride, 1Omm zinc sulphate, 5 mm dithiothreitol (DTT), 20% (v/v)
glycerol),equivalent amounts ofGST fusion proteins (as indicated),
approximately 1 ng of labelled probe and 0.1 mg ml-1 poly (dI.dC).
Gel-shifts were assayed directly on non-denaturing 6% (w/v) poly-
acrylamide gels. Footprinting reactions were initiatedby the addition
of 50 gl ofa 50 mm calcium chloride, 10 mm magnesium chloride
solution and 0.01 units of DNAase I (RQ1, Promega) and incu-
bated for 1 min at 37°C. Reactions were stopped with an equal
volume of 200 mm sodium chloride, 30 mM EDTA, 1% sodium
dodecyl sulphate (SDS). After phenol-chloroform-isoamyl
alcohol (25:24:1) extraction and ethanol precipitation, samples
were resuspended in 6 p1 of a 1:1 (v/v) mix of water-loading
buffer [0.1 M sodiumhydroxide-formamide 1:1 (v/v), 0.1% xylene
cyanol, 0.1% bromophenol blue and separated on 6% (w/v) dena-
turing polyacrylamide gels (Sequagel). Footprinted regions were
analysed by comparison with a DNA sequence of the probe
obtained with Sequenase 2 reagents (United States Biochemical)
and loaded on the same gel.
Each of the gel-shift and DNAase I footprinting assays were
repeated at leastthree times andrepresentative autoradiographs are
shown.
Cell culture and transient transfection assays
Primary mouse embryonic fibroblasts with the required p53 geno-
types were obtained using 15.5-day embryos from an inter-cross of
heterozygous p53 knock-out mice (p53+1-; Clarke et al, 1993) that
had been maintained on a mixed inbred strain background, then
inbredfor atleastthreegenerations onto the 129J strainbackground.
Cells were separately prepared from each individual embryo using
the method described by Hogan et al (1994), cultured to confluence
in 25-cm2 flasks and cryopreserved. Genomic DNA was extracted
from the liver and/or yolk-sac tissue dissected from each embryo
and the p53 genotype of the resultant cell lines was determined
using the polymerase chain reaction (PCR), as described by
Malcomson et al (1997). NIH-3T3, a cell line derived from mouse
embryonic fibroblasts, was obtained from the collection housed at
the SirWilliam Dunn School ofPathology (Oxford, UK).
All cells were cultured at 37°C, 5% carbon dioxide in
Dulbecco's modified Eagle medium (DMEM; Sigma) supple-
mented with 10% fetal calf serum (Hyclone), penicillin
(100 iu ml-'), streptomycin (0.1 mg ml-') and glutamine (2 mM).
For transient transfections, cells were plated at 150 000 cells per
35-mm dish and transfected the following day with lipofectamine
(Lipofectin, Life Technologies) according to the manufacturer's
protocol. A total of 2 jig ofplasmid DNA,comprising 1 jg ofthe
luciferase reporterplasmid, P3MM, plus 1 jg ofoneofthe expres-
sion vectors (pCMV-EGR, pCMV-KTS and pCMV+KTS or the
control vectorpCMV-REV), was used with 8 ,loflipofectamine.
After a 7-h exposure to the lipofectamine/DNA mixture in 1 ml of
serum-free medium (Opti-MEM, Life Technologies), the cells
were washed and re-fed with culture medium. After a48-h incuba-
tion, they were washed three times with PBS and lysed with 1X
Cell CultureLysis Reagent (Promega). Luciferase activity in 10 ,l
of cell lysate was measured with an Autolumat LB 953 lumi-
nometer (Berthold) using the Luciferase Assay System from
Promega. Total soluble protein in the lysates was measured spec-
trophotometrically by using the Protein Assay Dye from Bio-Rad.
Luciferase readings were adjusted relative to total protein levels to
control for variations in cell number. Transfection efficiencies
were monitoredby slot-blot analysis, in which lysate aliquots were
probed with a luciferase cDNA probe and the intensity ofthe blots
quantified by densitometry (NIH-Image), essentially as described
by Abken and Reifenrath (1992). Transient expression experi-
ments were repeated at least three times, with all samples being
treated in duplicate on each occasion.
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Figure 1 DNAase I footprinting of the Igf2 P3 promoter. The end-labelled
probe was incubated with increasing amounts (200 ng and 400 ng) of either.
EGR1, WT1[-KTS] or WT1[+KTS] fusion proteins and treated with DNAase I.
Protected regions, numbered 1-4, are highlighted by black boxes and their
sequences are given in Figure 2. As a negative control 500 ng of reverse
protein (Rev) was used
RESULTS
Identification of WT1 and EGR1 binding sites in the Igf2
P3 promoter
Binding of WT1[+KTS], WT1[-KTS] and EGR1 to the 1gJ2 P3
promoter was analysed by DNAase I footprinting. Both EGRI and
WT1[-KTS] ZF fusion proteins bound to several sites in the frag-
ment spanning nucleotides -162 to +70 ofP3 (Figure 1). Whereas
EGRI protected the regions between positions -128 and -94
(site 1), from -85 to -66 (site 2) and from -28 to -9 (site 4), four
protected regions were identified with the WT1[-KTS] GST
fusion protein. These were located at nucleotide positions -128 to
-87 (site 1), -81 to -62 (site 2), -56 to -47 (site 3), and from -28
to -9 (site 4). The three EGRI binding sites overlap with
WT1[-KTS] sites, but with the WT1[-KTS] footprints tending to
be longer than the EGRI footprints, which can be attributed to the
extra ZF in the WTl DNA binding domain. The degree ofprotec-
tion varied considerably between the different sites and with the
different fusion proteins. Although EGRI footprints are all equally
strong, most of the WTI[-KTS] footprints are much weaker, with
the exception of site 1, and WT1[+KTS] was shown to bind only
between positions -56 to -47 (site 3). Although representing a
very weak region ofprotection, site 3 is unique in being protected
by both forms of WT1 and not by EGR1. The nucleotide
sequences ofthe protected regions are listed in Figure 2.
Characterization of DNA binding by EGR1, WT1 and
DDS WT1 mutants
Gel-shift assays were carried out to further characterize the
binding affinities of EGRI and both WTI isoforms to Igf2 P3
(Figure 3). Quantification of the relative affinities was estimated
using densitometry of the autoradiographs and indicated that
WT1[-KTS] has a 3.8-fold greater affinity than WTI[+KTS],
whereas EGR1 binds with greatest affinity, at least 5 times higher
than WT1[-KTS] and 20 times higher than WTI[+KTS]. This is
consistent with the observed quantitative differences in protection
offootprinted sites.
To investigate the contribution of individual ZFs to DNA
binding, fusion proteins lacking either ZF1 or ZF4 were tested.
Although the removal of ZF1 from WT1[-KTS] resulted in
increased binding affinity (2.5-fold increase), the removal of ZF4
significantly reduced binding (6.8-fold decrease). In contrast,
deletion of ZFI from WTI[+KTS] decreased binding affinity
2.7 times, whereas the deletion of ZF4 showed little effect
(0.35-fold decrease).
To determine the effect ofDDS mutations on binding ofWT1 to
P3, mutations affecting amino acids directly involved in DNA
binding were represented in this study by transversions R394W,
D396N and D396G. The R394W mutation in ZF3 is the most
common point mutation in DDS patients (Little et al, 1993;
Coppes etal, 1993), whereas D396, also in ZF3, is the second most
frequently affected amino acid in DDS mutations. The binding of
both WT1[-KTS] and WT1[+KTS] to1gJ2 P3 was abolished by all
DDS missense mutations studied (Figure 4).
Regulation of expression from the Igf2 P3 promoter in
transient transfection assays
To establish the role of the identified EGR1 and WTI binding
sites in transcriptional regulation, transient transfection assays
were performed. NIH-3T3 fibroblasts were co-transfected with
pP3MM, an IgJ2 P3 promoter-luciferase reporter construct, and
either a control plasmid (pCMV-Rev) or an expression vector for
either EGR1, WT1[-KTS] or WT1[+KTS]. In these cells, co-
transfections with EGRI or any of the WTI isoforms resulted in
consistent repression of P3-driven luciferase expression (Figure
SA). EGR1 repressed luciferase expression to 57% of control
levels whereas co-transfection with WTI[-KTS] andWTl[+KTS]
resulted in repression to 53 and 36% ofcontrol levels respectively.
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Binding sites Protein Nucleotide positions Igf2 P3 sequences
Site 1 EGR1 -128 to -95 5'-GGAAGGGAGGGGGCGGGTGCAAGGGGGCGGG
-KTS -128 to -87 5'-GGAAGGAGGGAGGGGGCGGGTGCAAAGGGGGCGGGGGGAGTG
Site 2 EGR1 -85 to -66 5'-TCAGCAGAGaAGGGGGTGGGG -KTS -81 to -62 5'-CAGGGAGGGGGTGGGGGGTA
Site 3 -KTS -56 to -47 5'-GAGCCGGAC +KTS -56 to -47 5'-GAGCCGGAC
Site 4 EGR1 -28 to -9 5'-CATAAAAAaAGQACTG -KTS -28 to -9 5'-CATAAAAAGCGGAGGCACTG
B
Site la 5' G A G G G G G C G 3'
Site lb A A G G G G G C G
Site 2 G A G G G G G T G
Site3 G A G C C G G A C
Site4 G C G G A G G C A
EGR1 G C G G G G G C G
consensus T 1 T T T T
Figure 2 Igf2 P3 nucleotide sequences protected by EGR1 and WT1. (A) Protected regions 1-4 (as shown in Figure 1) are listed and nucleotide positions
given within the mouse lgf2sequence (Rotwein and Hall, 1990; position +1 is the transcriptional start site of exon 3). Underlined regions are the best fit to the
consensus EGR1 DNA-binding sequence 5'-GCGGGGGCG. (B) Alignment of best fit sequences with the EGR1 binding consensus. Arrows indicate nucleotides
contacted by specific amino acid residues as determined from crystallographic studies of EGR1:DNA complexes (Pavletich and Pabo, 1991; 1993)
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Figure 3 Gel electrophoretic mobility shift analysis of WT1 and EGR1 binding to the Igf2 P3 promoter. Binding of ZF regions of wild-type proteins (EGR1,
WT1[-KTS] and WT1[+KTS]) and of mutant WT1 isoforms lacking either ZF1 ([-KTS-ZF1 and +KTS-ZF1) or ZF4 ([-KTS-ZF4 and +KTS-ZF4). Rev is the
reverse GST-fusion protein used as a negative control
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Figure 4 Gel electrophoretic mobility shift assays to determine the effect of
Denys-Drash syndrome point mutations (R394W, D396G and D396N) on
binding to the Igf2 P3 promoter. Rev is the reverse GST-fusion protein used
as a negative control, and WT1[-KTS] was used as the positive control for
binding to Igf2 P3
To investigate the putative role of p53 in modulating the tran-
scriptional function ofWT1 (Maheswaran et al, 1993), the transient
transfection experiments were repeated in primary mouse embry-
onic fibroblasts which differed in the presence or absence of the
p53 gene (Figure SB). Contrary to expectation, we observed no
difference between co-transfections performed in either pS3+'+ or
p534- cells. The effect of both WT1 isoforms on 1gJ2 P3-driven
expression wasentirely consistentforbothcell genotypes ineachof
the six independent experiments and there was no statistically
significant difference in relative luciferase activity levels between
cells with different genotypes transfected with the same WT1
isoform (paired t-test, P> 0.05). Mostsignificantly, in contrast with
the observations in NIH-3T3 fibroblasts, in primary embryonic
fibroblasts WT1[-KTS] acted as an activator ofIgf2 P3 expression,
whereas WT1[+KTS] continued to behave as a repressor. On
average, WT1[-KTS] caused an approximately twofold induction
of luciferase levels and WT1[+KTS] repressed luciferase levels to
approximately 40% of controls. EGRI repressed transcription to
about 57% and 19% of control levels in pS3+'+ and p534- cells
respectively. Although these cells do not express endogenous WT1,
these experiments establish that the two WT1 isoforms can exert
opposite effects on the same gene construct in a given cell type.
DISCUSSION
Characterization of WT1 and EGR1 binding to the Igf2
P3 promoter
In this study we show that the transcription factors EGRI and
WT[-KTS] bind to overlapping regions of the mouse Igf2 P3
promoter, whereas WT1[+KTS] binds weakly and only to one of
the WT1[-KTS] sites. The sites mapped did not contain perfect
EGR1 consensus binding sequence (5'-GCGGGGGCG-3') but
various related sequences. Nevertheless, the alignment of these
sequences with the EGRI consensus binding sequence shows that
most of the nucleotides that diverge from the consensus occupy
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Figure 5 Transcriptional regulation of the Igf21 P3 promoter. Luciferase
activity in cells transiently transfected with the P3-luciferase reporter
construct along with constructs encoding CMV-driven murine EGR1,
WT1[-KTS], WT1[+KTS] orthe control vector pCMV-reverse, in which the
WT1 cDNA was inserted in the reverse orientati6n downstream of the CMV
promoter. (A) Co-transfections in NIH-3T3 fibroblasts. (B) Co-transfections in
p53 wild-type (p53t'+) and p53 knock-out (p534-) primary embryonic
fibroblasts. Bars show standard deviations calculated from multiple
independent experiments. *, p53 +/+; *, p53 -/-
positions that do not contact ZF amino acid residues, as predicted
fromEGRI:DNA co-crystallographic studies (Pavletich and Pabo,
1991 and 1993; Figure 2B). Notably, thebinding site with the most
divergent sequence (site 3) was notprotectedby EGRI and was the
only binding site for WT1[+KTS].
In WT1, ZF usage between the isoforms varies according to the
target sequences (Little et al, 1996). Our analysis of the binding
affinity ofZF deletion mutants showed that ZF 4 is crucial for the
higheraffinity binding ofWT1[-KTS]. When thisfinger is deleted
WT1[-KTS] binds with a much lower affinity, down to levels
equivalent to the much weaker binding [+KTS] isoform. This
suggests that whereas WT1[-KTS] binds through ZF 2, ZF 3 and
ZF 4, which are highly homologous to the three EGRI ZFs, the
insertion of the three amino acids, KTS, in the linker region
between ZFs 3 and 4 cancels the involvement ofZF4 inbinding to
this DNA target. Consistent with this, deletion of ZF 4 does not
affect WT1[+KTS] binding to Igf2 P3 sequences, as observed
previously in other WT1 target sequences (Caricasole et al, 1996;
Little et al, 1996).
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Binding to Igj2 P3 was completely abolished by all
Denys-Drash point mutations represented in this study (R394W,
D396N and D396G). A loss of DNA-binding by DDS mutant
WTl was previously reported to other targets (Little et al, 1995),
and is consistent with a dominant-negative mode of action in DDS
patients with heterozygous mutations of this type.
Transcriptional regulation of Igf2 P3 by WT1 and EGR1
WT1 loss of function has been implicated in a variety of genito-
urinary developmental anomalies as well as in the aetiology of
Wilms' tumour. However, the exact role WT1 plays in normal
development and tumorigenesis is not well understood. Although
we know that the WT1 protein can both repress and activate
transcription, the factors influencing this transcriptional activity
remain to be elucidated.
The tumour-suppressor protein p53 has been proposed to be a
modulator of WT1 activity after Maheswaran et al (1993) demon-
strated that it physically associates with WTI in transfected cells.
It was suggested that the interactions between the two proteins
would modulate the transcriptional activity of WT1, p53 acting as
a co-repressor. Evidence for this came from comparisons ofWT1
activity in NIH-3T3 fibroblast cells (which contain a wild-type
p53 gene) with Saos-2 osteosarcoma-derived cells (mutant for
p53). However, the difference between these two cell lines is
unlikely to be restricted to theirp53 status and in the present work
we observed that the p53 genotype did not influence WT1 regula-
tion of Igf2 P3 in mouse primary embryonic fibroblasts. By
deriving these cells from embryos originated by inter-crossing
heterozygous p53 knock-out mice, we worked with cells in which
the only essential difference was in thep53 gene, allowing a direct
comparison between p53+'+ and p53-' cells. We conclude that p53
is not involved in modulation ofWTI transcriptional regulation of
Igf2. This is consistent with available genetic evidence as p53 null
mice do not exhibit any developmental abnormalities of the
urogenital system (Donehower et al, 1992), something one might
expect ifp53 interaction was required for WT1 function.
In addition to co-factor interactions, which might be cell type-
specific, the difference between WT1 isoforms could influence
whether WT1 acts as a repressor or an activator of transcription.
Here, we report for the first time an instance in which the two WT1
ZF isoforms have opposite effects on the expression from a single
promoter. Contrary to what has previously been observed in co-
transfection experiments with WTI and IGF2 promoter-reporter
constructs, WTI[-KTS] is a transcriptional activator of the Igf2 P3
promoter in primary mouse embryonic fibroblasts. This may reflect
the cell-type specificity of WT1 action as the previous reports
referred to assays in established cell lines such as HepG2
(Drummond et al, 1992; 1994; Ward et al, 1995) or CVl (Lee and
Kim, 1996). Our own results when using NIH-3T3 cells were
consistent with these previous reports. We suggest that the use of
primary cell cultures, particularly at early passages, better reflects
physiological WTl activity. Furthermore, the finding that
WT1[-KTS] can activate 1gJ2 P3 (whereas WT1[+KTS] repressed
its activity) is consistent with two recent independent observations.
When RM1 Wilms' tumour cells stably transfected with
WT1[-KTS] were grown in vivo, a considerable induction of
endogenous IGF2 expression was observed (Nichols et al, 1995).
In addition, Menke et al (1996) reported that the stable transfection
of adenovirus-transformed baby rat kidney cells (Ad-BRK) with a
WTl[+KTS] vector significantly suppressed their tumorigenicity
while expression oftheWT1 [-KTS] protein stimulated the tumour
growth rate. The authors postulated that this could be explained if
the WT1[+KTS] protein down-regulates the expression of growth
factor, and growth factor receptor, genes whereas the WT1 [-KTS]
isoform up-regulates their expression. The observed repression of
Ig2 P3 by WT1 [+KTS] and its transactivation by WT1 [-KTS] are
entirely consistent with their hypothesis.
In contrast with WT1 [-KTS], with which it shares at least three
binding sites, EGRI repressed transcription driven from P3 in all
three different cell types tested. Although typically a transactivator
(Sukhatme, 1990), EGRI had been shown previously to function
as both an activator and repressor of transcription depending on
cell type (Wang et al, 1992) and a novel repression module has
since been identified (Gashler et al, 1993).
The strong repression observed with WT1[+KTS] seems incon-
sistent with its weak binding activity to Igf2 P3 in vitro. This could
be explained if binding by this isoform is greater in vivo. For
example, binding could be enhanced by the presence of transcrip-
tional co-factors, and it should be noted that the binding studies
were conducted using fusion proteins containing only the ZF
domains of WT1 and EGRI, whereas full-length proteins were
expressed from constructs used in the transient transfection assays.
Alternatively, WT1 [+KTS] may be acting at the post-transcrip-
tional level, by interference with mRNA splicing and/or transcript
sequestration through RNA binding. We have recently shown that
WT1 binds specifically to Igf2 exon 2 RNA (Caricasole et al,
1996) and WT1[+KTS] was found to be mainly associated with
splice factors in the nucleus (Larsson et al, 1995), both observa-
tions which support a post-transcriptional role for this protein.
The mechanism of WT1 action in tumorigenesis
It seems reasonable to assume that the WT1[-KTS] isoform could
function as an oncogene, at least in part, by up-regulating expres-
sion of IGF2 (and probably other growth factors), therefore
enhancing the ability of the cells to grow in an autocrine/paracrine
way. This would explain the intriguing observation that wild-type
WT1 is expressed in several tumours and tumour cell lines, such as
in the majority of human acute leukaemias (Miwa et al, 1992), in
ovarian tumours (Bruening et al, 1993) and in malignant meso-
thelioma (Amin et al, 1995) and that in a number of these tumours
WT1 expression could not be detected in the normal tissue counter-
part (Brieger et al, 1994; Rodeck et al, 1994; Menssen et al, 1995).
Furthermore, a few DDS patients have been characterized with
heterozygous germline mutations affecting the exon 9 splice donor
sequence, resulting in production of only WT1[-KTS] transcripts
from the mutant allele (Bruening and Pelletier, 1994). This
suggested that the observed WT1[-KTS] to WT1[+KTS] ratio of
expressed isoforms (Haber et al, 1991) needs to be strictly main-
tained for normal development. If, as we observed with an Igf2 P3
reporter gene, the two WT1 ZF isoforms can have opposite effects
on transcriptional regulation in vivo it might explain why their
levels have to be so finely balanced. We are currently attempting to
test this, as well as our other observations made in cell culture, in a
more physiologically relevant system by creating transgenic mice
overexpressing different WT1 isoforms.
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